TuHURA Biosciences, Inc. | Finanzwire

Basculer en Français

8596	Companies
140023	Keywords
75968	Articles
74765	Press releases

Headlines Articles Press releases TuHURA Biosciences, Inc.

Home
Companies
TuHURA Biosciences, Inc.

BRIEF

published on 03/11/2025 at 13:10, 22 days 7 hours ago

TuHURA Biosciences Appoints Dr. Craig L. Tendler to Board

Clinical Trials TuHURA Biosciences Oncology Drug Development Craig L. Tendler Immune Resistance
PRESS RELEASE

published on 03/11/2025 at 13:05, 22 days 7 hours ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
TuHURA Biosciences, Inc. appoints Dr. Craig Tendler with extensive experience in oncology drug development to its Board of Directors, enhancing advancement of cancer immunotherapy with novel technologies

Phase 3 Clinical Trial TuHURA Biosciences Cancer Immunotherapy Oncology Drug Development Craig Tendler
BRIEF

published on 03/10/2025 at 14:05, 23 days 6 hours ago

TuHURA Biosciences to Present at ROTH Conference

TuHURA Biosciences Immuno-oncology ROTH Conference Cancer Resistance IFx-2.0 Trial
PRESS RELEASE

published on 03/10/2025 at 14:00, 23 days 6 hours ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
TuHURA Biosciences, Inc. announces President and CEO James A. Bianco, M.D. will participate in a fireside chat at the 37th Annual ROTH Conference on March 18, 2025 at 8:30 AM PT in Dana Point, CA. Live webcast available on tuhurabio.com

Fireside Chat TuHURA Biosciences Immuno-oncology Live Webcast 37th Annual ROTH Conference
BRIEF

published on 02/19/2025 at 15:05, 1 month 11 days ago

TuHURA Biosciences, Inc. Engages in Virtual Investor Conference

TuHURA Biosciences Phase 3 Trial Virtual Conference Immune-oncology Cancer Resistance
PRESS RELEASE

published on 02/19/2025 at 15:00, 1 month 11 days ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
TuHURA Biosciences, Inc. announces participation in Virtual Investor 'Top 5 for ‘25' On-Demand Conference. Watch the on-demand video webcast on the company's website

TuHURA Biosciences Investment Community Immune-oncology Virtual Investor On-Demand Conference
BRIEF

published on 12/12/2024 at 14:50, 3 months 21 days ago

TuHURA Biosciences to Acquire Kineta in Strategic Merger

Merger Agreement Cancer Immunotherapy Checkpoint Inhibitors TuHURA Pipeline Kineta Acquisition
PRESS RELEASE

published on 12/12/2024 at 14:45, 3 months 21 days ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
TuHURA Biosciences, Inc. announces acquisition of Kineta, Inc. to expand late-stage pipeline with novel checkpoint inhibitor KVA12123 for cancer immunotherapy in 2025

Merger Agreement TuHURA Biosciences Cancer Immunotherapy KVA12123 Kineta Inc.
BRIEF

published on 11/25/2024 at 14:40, 4 months 7 days ago

TuHURA Biosciences Advances Key Cancer Immunotherapy Initiatives

TuHURA Biosciences Cancer Immunotherapy IFx-2.0 Phase 3 Trial VISTA Inhibiting Antibody FDA SPA Agreement
PRESS RELEASE

published on 11/25/2024 at 14:35, 4 months 7 days ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
TuHURA Biosciences, Inc. provides a business update on its innovative cancer immunotherapy technologies, including IFx-2.0 Phase 3 trial for Merkel Cell Carcinoma, potential KVA12123 acquisition, and key management appointments

TuHURA Biosciences Phase 3 Trial Cancer Immunotherapy IFx-2.0 KVA12123 Acquisition

Accesswire

Published on 04/02/2025 at 20:00, 13 minutes ago

Network-1 Announces Acquisition of Patent Portfolio
Published on 04/02/2025 at 17:25, 2 hours 48 minutes ago

SOBRsafe Announces Reverse Stock Split
Published on 04/02/2025 at 15:00, 5 hours 13 minutes ago

Doubleview Gold Corp 2025 Exploration Program
Published on 04/02/2025 at 14:00, 6 hours 13 minutes ago

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Published on 04/02/2025 at 14:00, 6 hours 13 minutes ago

Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City

View all ACCESSWIRE

EQS Group

Published on 04/02/2025 at 20:01, 11 minutes ago

Annual General Meeting of Deutsche Konsum REIT-AG successfully held
Published on 04/02/2025 at 20:01, 11 minutes ago

Travis Perkins: Publication of the Annual Report and Accounts 2024
Published on 04/02/2025 at 19:40, 32 minutes ago

LION E-Mobility AG starts successfully into the new 2025 financial year – Challenging market environment impacts 2024
Published on 04/02/2025 at 19:13, 1 hour ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/02/2025 at 19:05, 1 hour 7 minutes ago

Annual General Meeting of HUBER+SUHNER AG: Shareholders endorse all of the Board of Directors’ proposals

Les Echos

Published on 04/02/2025 at 18:05, 2 hours 8 minutes ago

Financial statements - 31 december 2024
Published on 04/02/2025 at 17:45, 2 hours 28 minutes ago

Aéroports de Paris SA - Voting rights as of 31 March 2025
Published on 04/02/2025 at 17:45, 2 hours 28 minutes ago

Availability of the Pre-Q1 2025 Sales Communication
Published on 04/02/2025 at 17:45, 2 hours 28 minutes ago

Information concerning the total number of voting rights and shares 2025 03 31
Published on 04/01/2025 at 17:45, 1 day 2 hours ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE